- Home
- TRUP vs KNSA Comparison
TRUP vs KNSA Comparison
Compare TRUP & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRUP
- KNSA
- Stock Information
- Founded
- TRUP 2000
- KNSA 2015
- Country
- TRUP United States
- KNSA United Kingdom
- Employees
- TRUP N/A
- KNSA N/A
- Industry
- TRUP Medical Specialities
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- TRUP Health Care
- KNSA Health Care
- Exchange
- TRUP Nasdaq
- KNSA Nasdaq
- Market Cap
- TRUP 2.1B
- KNSA 2.1B
- IPO Year
- TRUP 2014
- KNSA 2018
- Fundamental
- Price
- TRUP $49.38
- KNSA $28.04
- Analyst Decision
- TRUP Buy
- KNSA Strong Buy
- Analyst Count
- TRUP 6
- KNSA 6
- Target Price
- TRUP $53.80
- KNSA $39.33
- AVG Volume (30 Days)
- TRUP 565.7K
- KNSA 1.1M
- Earning Date
- TRUP 08-07-2025
- KNSA 07-22-2025
- Dividend Yield
- TRUP N/A
- KNSA N/A
- EPS Growth
- TRUP N/A
- KNSA N/A
- EPS
- TRUP N/A
- KNSA N/A
- Revenue
- TRUP $1,321,538,000.00
- KNSA $481,166,000.00
- Revenue This Year
- TRUP $11.30
- KNSA $37.21
- Revenue Next Year
- TRUP $6.01
- KNSA $5.32
- P/E Ratio
- TRUP N/A
- KNSA N/A
- Revenue Growth
- TRUP 14.08
- KNSA 59.45
- 52 Week Low
- TRUP $28.73
- KNSA $17.82
- 52 Week High
- TRUP $57.90
- KNSA $30.69
- Technical
- Relative Strength Index (RSI)
- TRUP 41.85
- KNSA 51.09
- Support Level
- TRUP $51.07
- KNSA $27.06
- Resistance Level
- TRUP $53.61
- KNSA $29.25
- Average True Range (ATR)
- TRUP 2.14
- KNSA 0.97
- MACD
- TRUP -0.92
- KNSA -0.06
- Stochastic Oscillator
- TRUP 0.98
- KNSA 50.83
About TRUP Trupanion Inc.
Trupanion Inc is a specialty insurance products provider in the United States. Its core business is the sale of insurance products tailor-made for pets, especially cats and dogs. It operates in two business segments: The subscription business segment generates revenue primarily from subscription fees related to the Company's direct-to-consumer products and Other business segment is comprised of revenue from other product offerings that generally have a business-to-business relationship and a different margin profile than subscription business segment, including revenue from writing policies on behalf of third parties and revenue from other products and software solutions.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.